Purple Biotech Ltd. reported earnings of per PPBT share on Nov 13, 2026, falling short of analysts' expectations by
| Report Date | Nov 13, 2026 |
|---|---|
| Forecasted EPS | -$ 2.88 |
| Last Year's EPS | -$ 7.11 |
| EPS YoY Change |
Out of the last 55 earnings reporting periods, Purple Biotech Ltd. beat analysts’ expectations 4 times and fell short of expectations 23 time(s). Purple Biotech Ltd. reported earnings per share of in the last report surpassing an estimated EPS of -$ 2.88 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 13, 2026 | -$ 2.88 | -$ 4.00 | - | |
| Aug 7, 2026 | -$ 0.98 | $ 1.07 | -$ 1.70 | |
| May 15, 2026 | -$ 3.80 | -$ 0.09 | -$ 2.60 | |
| Mar 13, 2026 | -$ 3.40 | -$ 19.85 | -$ 13.70 | |
| Nov 14, 2025 | -$ 2.60 | -$ 2.90 | -$ 16.00 | |
| Aug 6, 2025 | -$ 2.10 | -$ 4.00 | -$ 30.00 | |
| May 21, 2025 | - | -$ 1.70 | -$ 64.00 | |
| Mar 10, 2025 | -$ 2.20 | -$ 2.60 | -$ 42.00 | |
| Nov 15, 2024 | -$ 12.00 | -$ 13.70 | -$ 46.00 | |
| Aug 16, 2024 | -$ 0.16 | -$ 16.00 | -$ 42.00 | |
| May 21, 2024 | -$ 0.20 | -$ 30.00 | -$ 60.00 | |
| Mar 5, 2024 | -$ 34.00 | -$ 64.00 | -$ 0.27 | |
| Nov 21, 2023 | -$ 44.00 | -$ 42.00 | -$ 0.20 | |
| Aug 22, 2023 | -$ 5.13 | -$ 46.00 | -$ 82.00 | |
| May 16, 2023 | -$ 0.39 | -$ 42.00 | -$ 50.00 | |
| Feb 8, 2023 | -$ 5.00 | -$ 60.00 | -$ 35.83 | |
| Nov 8, 2022 | -$ 0.21 | -$ 0.27 | -$ 41.40 | |
| Aug 4, 2022 | - | -$ 0.20 | -$ 75.35 | |
| May 12, 2022 | - | -$ 82.00 | -$ 16.00 | |
| Feb 9, 2022 | - | -$ 50.00 | -$ 1.29 |
Purple Biotech Ltd.’s stock was trading at $ 1.56 on Nov 12, 2026 a day before the last earnings report was released.
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 13, 2026 | | $ 1.56 | ||
| Aug 7, 2026 | $ 1.07 | $ 1.41 | $ 1.50 | |
| May 15, 2026 | -$ 0.09 | $ 3.69 | $ 3.78 | |
| Mar 13, 2026 | -$ 19.85 | $ 3.84 | $ 4.09 | |
| Nov 14, 2025 | -$ 2.90 | $ 7.40 | $ 7.20 | |
| Aug 6, 2025 | -$ 4.00 | $ 22.60 | $ 21.50 | |
| May 21, 2025 | -$ 1.70 | $ 24.10 | $ 24.90 | |
| Mar 10, 2025 | -$ 2.60 | $ 28.10 | $ 26.50 | |
| Nov 15, 2024 | -$ 13.70 | $ 25.20 | $ 25.50 | |
| Aug 16, 2024 | -$ 16.00 | $ 72.38 | $ 73.56 | |
| May 21, 2024 | -$ 30.00 | $ 112.63 | $ 136.00 | |
| Mar 5, 2024 | -$ 64.00 | $ 166.00 | $ 163.00 | |
| Nov 21, 2023 | -$ 42.00 | $ 200.00 | $ 204.00 | |
| Aug 22, 2023 | -$ 46.00 | $ 254.00 | $ 240.00 | |
| May 16, 2023 | -$ 42.00 | $ 362.00 | $ 377.00 | |
| Feb 8, 2023 | -$ 60.00 | $ 378.00 | $ 376.00 | |
| Nov 8, 2022 | -$ 0.27 | $ 426.00 | $ 398.00 | |
| Aug 4, 2022 | -$ 0.20 | $ 498.00 | $ 498.00 | |
| May 12, 2022 | -$ 82.00 | $ 588.00 | $ 584.00 | |
| Feb 9, 2022 | -$ 50.00 | $ 594.00 | $ 590.00 |
Purple Biotech Ltd. released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Purple Biotech Ltd. beat analysts’ expectations during the last earnings period by
